Posts Tagged ‘John Deeken’
Why subspecialized cancer care matters
John Deeken, MD, is president of the Inova Schar Cancer and Medical Director for the Inova Schar Head and Neck Cancer Program. He is board-certified in medical oncology and specializes in head and neck cancers. When you or someone you love is diagnosed with cancer, one of the most important decisions you face is choosing…
Read MoreFighting a Cancer Epidemic With a Vaccine
John Deeken, MD, is president of the Inova Schar Cancer Institute. He is board-certified in medical oncology and specializes in head and neck cancers. Quitting smoking. Eating better. Wearing sunscreen. These are all well-known behaviors that can lower cancer risk. But there’s another, less-heralded way to reduce cancer odds: get vaccinated. Specifically, vaccination against the…
Read More‘What’s Really Important to Patients?’ Doctors Are Asking, WebMD
John Whyte, MD, MPH with WebMD spoke with Inova Schar Cancer Institute President about how the new building concept was shaped by patients.
Read MoreJohn McCain’s cancer: What is glioblastoma?, WUSA 9
Senator John McCain announced he was diagnosed with a primary brain tumor known as a glioblastoma. Our own Dr. John Deeken from the Inova Center for Personalized Health specializes in treating brain cancer and spoke with WUSA 9 about a gliobastoma diagnosis and treatment options. Watch more.
Read MoreGenomic medicine informing patient care, HIMSS ’17 TV
John Deeken, MD, discusses the mission of Inova Translational Medicine Institute and how genomic sequencing is changing the culture of patient care. Watch more.
Read MoreGenomic medicine goes mainstream, Modern Healthcare
Dr. Craig Cheifetz and Dr. John Deeken share how genomic medicine are being used in medicine. Read more.
Read MoreDr. John Deeken Spoke with WUSA 9 about Inova’s Partnering in Clinical Research on ‘Chemo Brain’
Dr. Deeken and his colleagues at Inova Cancer Center are researching ways to help those who suffer from chemo brain. They are starting a clinical trial in collaboration with Stanford University Medical Center to understand the genetics of this chemotherapy side effect.
Read More